Prestige Biologics Amends CB Conversion Price
프레스티지바이오로직스
334970
Signal Score
Historical Avg Return (5d)
+0.33%
Data Coverage
100%n=2377
Risk-adjusted indicator based on 2377 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Previous Minimum Adjusted Conversion Price: 2,747 KRW/Share
- • New Minimum Adjusted Conversion Price: 2,474 KRW/Share
- • YTC (Yield to Call) for Early Redemption: 4.83% (annual compound interest)
AI Analysis Summary
Prestige Biologics Co., Ltd. has amended its Material Fact Report regarding the decision to issue convertible bonds. The key change is a reduction in the minimum adjusted conversion price from 2,747 KRW per share to 2,474 KRW per share due to market price decline. This adjustment increases the potential dilution for existing shareholders. The convertible bonds include an early redemption option for the issuer with a guaranteed yield to call (YTC) of 4.83% annual compound interest. The amendment reflects a more favorable conversion rate for bondholders, potentially leading to increased share dilution upon conversion, which is a negative for existing shareholders.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.